AU2010243368C1 - Use of PUFAs to treat nerve damage - Google Patents
Use of PUFAs to treat nerve damage Download PDFInfo
- Publication number
- AU2010243368C1 AU2010243368C1 AU2010243368A AU2010243368A AU2010243368C1 AU 2010243368 C1 AU2010243368 C1 AU 2010243368C1 AU 2010243368 A AU2010243368 A AU 2010243368A AU 2010243368 A AU2010243368 A AU 2010243368A AU 2010243368 C1 AU2010243368 C1 AU 2010243368C1
- Authority
- AU
- Australia
- Prior art keywords
- cis
- group
- unsubstituted
- alkyl
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0907601.9A GB0907601D0 (en) | 2009-05-01 | 2009-05-01 | Novel methods |
| GB0907601.9 | 2009-05-01 | ||
| PCT/GB2010/000817 WO2010125330A1 (en) | 2009-05-01 | 2010-04-22 | Use of pufas to treat nerve damage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010243368A1 AU2010243368A1 (en) | 2011-12-15 |
| AU2010243368B2 AU2010243368B2 (en) | 2013-10-24 |
| AU2010243368C1 true AU2010243368C1 (en) | 2014-04-03 |
Family
ID=40792178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010243368A Ceased AU2010243368C1 (en) | 2009-05-01 | 2010-04-22 | Use of PUFAs to treat nerve damage |
Country Status (14)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| ES2727387T3 (es) * | 2013-11-15 | 2019-10-15 | Ds Biopharma Ltd | Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3261684D1 (en) * | 1981-05-12 | 1985-02-07 | Ici Plc | Pyrrole derivatives |
| US4532254A (en) * | 1983-03-17 | 1985-07-30 | Kaken Pharmaceutical Co., Ltd. | Inhibitor of aldose reductase |
| AU599515B2 (en) * | 1987-09-16 | 1990-07-19 | Taiho Pharmaceutical Co., Ltd. | Thienopyrimidine derivatives |
| EP2140863A1 (en) * | 1993-06-09 | 2010-01-06 | Martek Biosciences Corporation | Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders |
| US7015249B1 (en) * | 1997-12-12 | 2006-03-21 | Purdue Research Foundation | Methods and compositions for treating diabetes |
| US6107349A (en) * | 1998-04-16 | 2000-08-22 | Mantynen; Philip R. | Method and composition for treating psoriasis |
| GB9827391D0 (en) * | 1998-12-11 | 1999-02-03 | Fundation O N C F | Aldose reductase inhibitors and pharmaceutical compositions |
| CA2304906A1 (en) * | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| AU2002304931A1 (en) * | 2001-06-08 | 2002-12-23 | University Of British Columbia | Methods for treating disorders of the nervous and reproductive systems |
| ES2536710T3 (es) * | 2002-03-25 | 2015-05-27 | Arimed Inc. | Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A |
| WO2006137435A1 (ja) * | 2005-06-22 | 2006-12-28 | National University Corporation Gunma University | Gタンパク質共役型受容体g2aの作動薬、及びg2a活性調節薬のスクリーニング方法 |
| EP2179999A4 (en) * | 2007-12-18 | 2011-06-08 | Univ Toyama Nat Univ Corp | CONDENSED TRICYCLIC COMPOUND WITH ALDOSIS REDUCTASE HARMFUL EFFECT |
-
2009
- 2009-05-01 GB GBGB0907601.9A patent/GB0907601D0/en not_active Ceased
-
2010
- 2010-04-22 SG SG2011080280A patent/SG175848A1/en unknown
- 2010-04-22 WO PCT/GB2010/000817 patent/WO2010125330A1/en not_active Ceased
- 2010-04-22 BR BRPI1009922A patent/BRPI1009922A2/pt not_active IP Right Cessation
- 2010-04-22 US US13/318,420 patent/US20120122982A1/en not_active Abandoned
- 2010-04-22 CA CA2762009A patent/CA2762009C/en not_active Expired - Fee Related
- 2010-04-22 CN CN201080023442.8A patent/CN102448453B/zh not_active Expired - Fee Related
- 2010-04-22 NZ NZ596674A patent/NZ596674A/xx not_active IP Right Cessation
- 2010-04-22 MX MX2011011615A patent/MX2011011615A/es active IP Right Grant
- 2010-04-22 KR KR1020117028669A patent/KR101664518B1/ko not_active Expired - Fee Related
- 2010-04-22 EP EP10717725A patent/EP2424519A1/en not_active Withdrawn
- 2010-04-22 JP JP2012507808A patent/JP5608220B2/ja not_active Expired - Fee Related
- 2010-04-22 AU AU2010243368A patent/AU2010243368C1/en not_active Ceased
-
2011
- 2011-11-22 ZA ZA2011/08571A patent/ZA201108571B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| NEGISHI MAYUMI ET AL, EXP. BIOLOGY AND MEDICINE, VOL. 229, NO 10, NOV 2004, PAGES 1053-1060 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2762009C (en) | 2016-11-22 |
| JP5608220B2 (ja) | 2014-10-15 |
| AU2010243368A1 (en) | 2011-12-15 |
| EP2424519A1 (en) | 2012-03-07 |
| GB0907601D0 (en) | 2009-06-10 |
| KR20120023729A (ko) | 2012-03-13 |
| SG175848A1 (en) | 2011-12-29 |
| AU2010243368B2 (en) | 2013-10-24 |
| CA2762009A1 (en) | 2010-11-04 |
| KR101664518B1 (ko) | 2016-10-11 |
| WO2010125330A1 (en) | 2010-11-04 |
| NZ596674A (en) | 2013-09-27 |
| JP2012525362A (ja) | 2012-10-22 |
| BRPI1009922A2 (pt) | 2016-03-15 |
| MX2011011615A (es) | 2012-01-27 |
| US20120122982A1 (en) | 2012-05-17 |
| CN102448453A (zh) | 2012-05-09 |
| CN102448453B (zh) | 2016-07-06 |
| ZA201108571B (en) | 2013-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2866067C (en) | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia | |
| Lee et al. | Palmitic acid methyl ester is a novel neuroprotective agent against cardiac arrest | |
| MX2015006390A (es) | Metodos y composiciones para incrementar localmente la grasa corporal. | |
| CN117377476B (zh) | 治疗与化学疗法诱发的周围神经病变相关的疼痛 | |
| IL270127B2 (en) | A topical pharmaceutical preparation that includes at least amitriptyline, for the treatment of peripheral nerve pain | |
| AU2010243368B2 (en) | Use of PUFAs to treat nerve damage | |
| JP2016540771A (ja) | セロトニン−ノルアドレナリン再取り込み阻害薬(snri)およびシグマ受容体リガンドの組み合わせ | |
| JP2006143708A (ja) | 神経変性疾患治療用医薬 | |
| AU2006275824B2 (en) | Method of improving wakefulness | |
| JP2021505668A (ja) | 併用療法(睡眠障害およびcns障害)において使用するためのnmda受容体モジュレーター(ラパスチネル)の組合せ | |
| JP2012525362A5 (cg-RX-API-DMAC10.html) | ||
| KR102721799B1 (ko) | 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물 | |
| WO2022004788A1 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| US8975298B2 (en) | Therapeutic agent for pain | |
| CN116987091B (zh) | 用于治疗癫痫发作疾病的药物及其制备方法 | |
| KR20250010571A (ko) | 신규한 고리 구조의 트리아졸 화합물, 이의 제조방법 및 이의 용도 | |
| JP6216913B1 (ja) | 医薬組成物 | |
| US20250064776A1 (en) | Treatment of amyotrophic lateral sclerosis using pkc activators | |
| Jang et al. | Effects of propofol administration rates on cardiopulmonary function and anaesthetic depth during anaesthetic induction in rats | |
| TWI533871B (zh) | 萘并[2,3-f]喹喔啉-7,12-二酮化合物緩解疼痛的應用 | |
| CN117530937A (zh) | Idebenone在制备预防和/或治疗肌腱损伤的药物中的应用 | |
| WO2020262317A1 (ja) | 認知症の治療及び予防薬 | |
| Burton et al. | (301) Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the transition to a chronic pain state | |
| Patil et al. | (300) Prolactin regulates sensory neurons in a female-specific manner at their peripheral and central terminals and not at their cell bodies | |
| CN101242836A (zh) | 改善觉醒状态的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 DEC 2013 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 DEC 2013 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |